Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 286

Sort by

Sort Order Select

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Rami S. Komrokji, MD, Steffen Koschmieder, MD, Alessandro M. Vannucchi, MD, Tymara Berry, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Libo Sun, PhD, Fei Huang, PhD, Ying Wan, PhD, Faye Feller, MD, Aleksandra Rizo, MD PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-138915

Published: 2020

Journal Articles

The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions

Matteo Della Porta, Uwe Platzbecker, Valeria Santini, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Rodrigo Ito, Pierre Fenaux, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140284

Published: 2020

Journal Articles

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Tymara Berry, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138818

Published: 2020

Journal Articles

To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study

Rami S. Komrokji, MD, Brady L. Stein, MD MHSc, Robyn M. Scherber, MD, Patricia Kalafut, PhD, Haobo Ren, PhD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 49–51.

https://doi.org/10.1182/blood-2020-134958

Published: 2020

Journal Articles

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

David A. Sallman, MD, Hany Elmariah, MD MS, Kendra L. Sweet, MD MS, Chetasi Talati, MD, Asmita Mishra, MD, Linda L. Kelley, PhD, Amy Lankford, PhD, Tim Chan, PhD, Rutul R Shah, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Helen Sabzevari, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139417

Published: 2020

Journal Articles

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Fei Huang, PhD, Aleksandra Rizo, MD PhD, Libo Sun, PhD, Ying Wan, PhD, Alessandro M. Vannucchi, MD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138823

Published: 2020

Journal Articles

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-137232

Published: 2020

Journal Articles

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

Virginia Olivia Volpe, MD, Najla Al Ali, M.Sc, Onyee Chan, MD, Eric Padron, MD, David A. Sallman, MD, Rami S. Komrokji, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-138833

Published: 2020

Journal Articles

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Mohammad O Hussaini, MD, David A. Sallman, MD, Dana Elise Rollison, PhD, Eric Padron, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139710

Published: 2020

Journal Articles

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Tymara Berry, MD, Faye Feller, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138905

Published: 2020

Journal Articles

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Seongseok Yun, MDPhD, David Gajzer, MD, Najla Al Ali, M.Sc, Nicole D. Vincelette, PhD, Pukhraz Basra, MBBS, Chetasi Talati, MD, Andrew T. Kuykendall, MD, Eric Padron, MD, Kendra Sweet, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A. Sallman, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137116

Published: 2020

Journal Articles

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study

Esther Natalie Oliva, MD, Uwe Platzbecker, Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Professor, Valeria Santini, Mikkael A. Sekeres, Rami S. Komrokji, MD, Jeevan K. Shetty, Derek Tang, Shien Guo, Weiqin Liao, George Zhang, Xianwei Ha, Rodrigo Ito, Jennifer Lord-Bessen, Jay T. Backstrom, Pierre Fenaux, MD PhD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136276

Published: 2020

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 4581.

https://doi.org/10.1182/blood-2019-125077

Published: 2019

Journal Articles

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Chetasi Talati, MD, Ryan J Caddell, PharmD, BCOP, Katherine Tobon, PharmD, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Eric Padron, MD, Hugo F. Fernandez, MD, Alan F. List, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 2636.

https://doi.org/10.1182/blood-2019-129166

Published: 2019

Journal Articles

Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)

Hannah Newman, BS, Anthony M. Hunter, MD, Christopher Letson, BS, Amy E. DeZern, MD, Maria E Balasis, William Dominguez-Viqueira, PhD, Alexis Vedder, BS, Traci Kruer, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Gail J. Roboz, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 2984.

https://doi.org/10.1182/blood-2019-128541

Published: 2019

Journal Articles

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

Andrew T Kuykendall, MD, Anthony Hunter, MD, Ling Zhang, MD, Eric Padron, MD, Chetasi Talati, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 2956.

https://doi.org/10.1182/blood-2019-130661

Published: 2019

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

SF3B1 Splicing Mutation in the Context of Therapy Related MDS

U2AF1 and EZH2 Mutations Are Associated with Non-Immune Hemolytic Anemia in Myelodysplastic Syndromes

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

High MYC Protein Expression in MDS Is Associated with Early Transformation to AML

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Email alerts

ASH Publications

American Society of Hematology